Quick Answer
Annovis Bio, Inc. reported R&D Expense of $25.22 million for fiscal year 2025.
Annovis Bio, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $25.22M | +26.1% |
| 2024 | $20.00M | -48.5% |
| 2023 | $38.79M | +134.9% |
| 2022 | $16.52M | +94.8% |
| 2021 | $8.48M | +177.6% |
| 2020 | $3.05M | +293.4% |
| 2019 | $776.3K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.29M | +133.9% | +21.9% |
| June 30, 2025 | $5.16M | -10.8% | +3.0% |
| March 31, 2025 | $5.01M | -23.1% | +86.3% |
| September 30, 2024 | $2.69M | -80.6% | -53.5% |
| June 30, 2024 | $5.79M | -30.0% | -11.2% |
| March 31, 2024 | $6.51M | -16.3% | -52.9% |
| September 30, 2023 | $13.84M | +235.6% | +67.5% |
| June 30, 2023 | $8.26M | +104.8% | +6.1% |
- Annovis Bio, Inc. showed an increase of +26.1% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Annovis Bio, Inc.’s r&d expense has grown by 3148.4% (from $776.3 thousand to $25.22 million).
- The most recent figure is from Annovis Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: